Skip to main content
55th ASAM Annual Conference Main banner
Final Program


Conference Program
Back

Collaborative Session

Concurrent Sessions #5

NIDA CTN Research Updates: Treatments for Stimulant Use Disorders
Developed in Collaboration with the National Institute on Drug Abuse

Saturday, April 6, 2024
10:30 AM – 11:45 AM  
There are no FDA approved medications for the management of stimulant use disorders. However, preliminary and emerging evidence from the NIDA Clinical Trials Network exploring the role of medications and other interventions in the management of these disorders, provide suggestions for novel pathways and potential new effective treatments.

Learning Objectives:

Learners will be able to:
  • Upon completion of the focus session, the participant will be able to demonstrate an increased knowledge of pharmacotherapy options for the management of stimulant use disorders.
  • Upon completion of the focus session, the participant will be able to discover the mechanisms and utility of brain stimulation techniques including transcranial magnetic stimulation in the management of stimulant use disorders.
  • Upon completion of the focus session, the participant will be able to articulate the value of artificial intelligence techniques in evaluating and repurposing existing medications in the management of stimulant use disorders.